Latest Commercial Rollout News

InteliCare Holdings has appointed seasoned healthcare executive Angus Cameron as CEO to lead its transition from pilot projects to full-scale commercial deployment following a major aged care contract.

Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for its Remplir™ nerve repair product in the UK, positioning itself for a rapid commercial launch pending regulatory approval.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

Green360 Technologies has successfully raised $4.5 million to back the commercial rollout of its Eco-Clay low-carbon cement product, aiming for market entry in the first half of 2026.

FBR Limited has locked in a binding $400,000–$450,000 Wall as a Service® contract with AMOVEO, marking a key step in deploying its Hadrian® robotic construction technology at scale. The company also inked a strategic MOU to pilot a hybrid robotic-modular housing solution targeting Australia’s affordable housing shortage.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

RocketBoots Limited reported a steep 71.75% drop in profit after tax to a $2.36 million loss for the half-year ending December 2025, despite a modest revenue increase. The company’s future hinges on a transformative $9.1 million annual recurring revenue contract with a tier-one multinational retailer and a recent $7 million capital raise.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

Nanosonics Limited reported a 9% revenue increase in the first half of FY26, driven by a growing installed base and recurring sales, while advancing the commercial rollout of its new CORIS endoscope reprocessing system.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Alcidion has secured regulatory approval for its AI-powered clinical tool in Australia and the UK, paving the way for commercial rollout in its largest markets. This milestone strengthens its position in healthcare technology and opens new sales avenues.